fen1

FEN1-IN-1 (LNT-1) is an inhibitor of flap endonuclease 1 (FEN1). FEN1-IN-1 binds to the active site of FEN1. It partly achieves inhibition by the co-ordination of Mg2+ ions.

FEN1-IN-2 is a selective and potent inhibitor of flap endonuclease 1 (FEN1), inhibits FEN1 and XPG, has potential anticancer activity, and can be used to study DNA damage repair.

FEN1-IN-4 (FEN1 Inhibitor C2) is an inhibitor of human flap endonuclease-1 (hFEN1)

FEN1-IN-8 (compound 15) is a selective inhibitor of FEN1, with an IC50 value of less than 100 nM for FEN1 and an IC50 value ranging from 100 nM to 1 μM for EXO1. It is applicable in colorectal and gastric cancer studies.

FEN1-IN-5 (compound 12A) is a potent inhibitor of Flap endonuclease-1 (FEN1) with an IC50 of 12 nM, contributing to DNA repair mechanisms [1].

FEN1-IN-6 (compound 9) is a potent Flap endonuclease-1 (FEN1, IC50 = 10 nM) inhibitor, crucial for DNA damage repair in mammalian cells, and also targets the related endonuclease xeroderma pigmentosum G (XPG) with an IC50 of 23 nM [1].

FEN1-IN-7 (compound 16), a selective Flap endonuclease-1 (FEN1) inhibitor with an IC50 of 18 nM, plays a role in DNA damage repair in mammalian cells. Additionally, it targets the related endonuclease, xeroderma pigmentosum G (XPG), with an IC50 of 3.04 μM. FEN1-IN-7 enhances the sensitivity of cancer cells to potent DNA alkylating or methylating agents [1].

FEN1-IN-3 is a human flap endonuclease-1 ( hFEN1 ) inhibitor that stabilizes hFEN1 with an EC 50 of 6.8 μM .

FEN1-IN-SC13 is a potent inhibitor of DNA fragmentation endonuclease 1 (FEN1).

Ibuprofen-13C,D3 is a carbon-13 and deuterium-labeled form of Ibuprofen (TMSM-1345). It acts as an inhibitor of COX-1 and COX-2 with IC50 values of 13 μM and 370 μM, respectively, and possesses anti-inflammatory properties.

Ibuprofen-13C6 is a 13C-labeled form of Ibuprofen (T1394). Ibuprofen ( (±)-Ibuprofen) acts as an orally active COX-1 selective inhibitor with an IC50 of 13 μM. It inhibits cell proliferation and angiogenesis while inducing apoptosis. Additionally, Ibuprofen (T1394) functions as a non-steroidal anti-inflammatory agent and a nitric oxide (NO) donor. It is used in research involving pain, swelling, inflammation, infections, immunology, and cancer.

trans-Hydroxy Loxoprofen-13C-D3 (Mixture of Diastereomers) the 13C and deuterated compound of trans-Hydroxy Loxoprofen. trans-Hydroxy Loxoprofen has a CAS number of 371753-19-4.

Ibuprofen-13C6 (Standard) is a reference standard of Ibuprofen-13C6 intended for quantitative analysis, quality control, and related biochemical research applications. Ibuprofen-13C6 ((±)-Ibuprofen-13C6) is a 13C-labeled form of Ibuprofen. Ibuprofen ((±)-Ibuprofen) acts as an orally active COX-1 selective inhibitor with an IC50 of 13 μM. It inhibits cell proliferation and angiogenesis while inducing apoptosis. Additionally, Ibuprofen functions as a non-steroidal anti-inflammatory agent and a nitric oxide (NO) donor. It is used in research involving pain, swelling, inflammation, infections, immunology, and cancer.

Ibuprofen-13C,D3 (Standard) is a reference standard of Ibuprofen-13C,D3 intended for quantitative analysis, quality control, and related biochemical research applications. Ibuprofen-13C,d3 is a carbon-13 and deuterium-labeled form of Ibuprofen. It acts as an inhibitor of COX-1 and COX-2 with IC50 values of 13 μM and 370 μM, respectively, and possesses anti-inflammatory properties.

MU1409 is an MRE11 nuclease inhibitor with an IC50 of 12.1 μM. It also inhibits FEN1 and EXO1, with IC50 values of 24.2 μM and 176.4 μM, respectively. MU1409 impacts cellular DNA repair and prevents the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for studying BRCA2 mutation-induced cancers.

MSC778 is a selective and orally active inhibitor of flap endonuclease 1 (FEN1), with an IC50 of 3 nM and a KD of 2.9 nM. It exhibits 145-fold, 516-fold, and 65-fold selectivity over EXO1, GEN1, and XPG, respectively. MSC778 selectively targets BRCA2-deficient cells and enhances the tumor-stalling activity of Niraparib in BRCA2 KO DLD-1 mouse xenografts. It is applicable in colorectal cancer research.

JFD00950 is a human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1.

NSC-13755 is a human flap endonuclease 1 (FEN1) inhibitor.